Status:
UNKNOWN
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Heparin-induced Thrombocytopenia
Eligibility:
All Genders
18-100 years
Brief Summary
Heparin-induced thrombocytopenia (HIT) is a rare but potentially serious complication of heparin therapy. , argatroban is the alternative anticoagulant of choice in patients with suspected HIT and ren...
Detailed Description
The study plan to set up a multicenter biobank of plasmas from patients treated with argatroban for suspected HIT in 10 French hematology laboratories (Dijon, Nantes, Tours, Lille, Bordeaux, Nancy, St...
Eligibility Criteria
Inclusion
- patients suspected of having HIT in any department, including ECMO in the 10 centers
- patient starting a treatment with argatroban.
- major patients
Exclusion
- Minor patients
- Patient under legal protection (guardianship or curatorship)
- Patient objecting to re-use of data and samples
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06066762
Start Date
November 1 2023
End Date
June 1 2025
Last Update
October 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Bichat-Claude Bernard
Paris, France, 75018